Dataset Information


Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation.

ABSTRACT: Inhibiting lipogenesis prevents hepatic steatosis in rodents with insulin resistance. To determine if reducing lipogenesis functions similarly in humans, we developed MK-4074, a liver-specific inhibitor of acetyl-CoA carboxylase (ACC1) and (ACC2), enzymes that produce malonyl-CoA for fatty acid synthesis. MK-4074 administered to subjects with hepatic steatosis for 1 month lowered lipogenesis, increased ketones, and reduced liver triglycerides by 36%. Unexpectedly, MK-4074 increased plasma triglycerides by 200%. To further investigate, mice that lack ACC1 and ACC2 in hepatocytes (ACC dLKO) were generated. Deletion of ACCs decreased polyunsaturated fatty acid (PUFA) concentrations in liver due to reduced malonyl-CoA, which is required for elongation of essential fatty acids. PUFA deficiency induced SREBP-1c, which increased GPAT1 expression and VLDL secretion. PUFA supplementation or siRNA-mediated knockdown of GPAT1 normalized plasma triglycerides. Thus, inhibiting lipogenesis in humans reduced hepatic steatosis, but inhibiting ACC resulted in hypertriglyceridemia due to activation of SREBP-1c and increased VLDL secretion.


PROVIDER: S-EPMC5603267 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

2006-01-01 | S-EPMC1366503 | BioStudies
2009-01-01 | S-EPMC2629817 | BioStudies
2007-01-01 | S-EPMC1820479 | BioStudies
2018-01-01 | S-EPMC6251774 | BioStudies
2020-01-01 | S-EPMC6986730 | BioStudies
2008-01-01 | S-EPMC2612019 | BioStudies
| S-EPMC3031740 | BioStudies
| S-EPMC6643297 | BioStudies
2013-01-01 | S-EPMC4965268 | BioStudies
2015-01-01 | S-EPMC4578927 | BioStudies